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We appreciate the comments of Cai and Yang, but we
respectfully disagree with several of their criticisms.1, 2
First, this study was not a systematic review. It is a
pooled analysis of individual patient data and data on
safety for each dose of medication are provided. Never-
theless, there is no difference in safety or tolerability
regardless of dose. This is unsurprising as less than 1%
of rifaximin is absorbed.
Second, the appropriate dose of rifaximin for treat-
ment of nonconstipation predominant irritable bowel
syndrome (non-C IBS) is clear. Based on the data in
over 1600 patients in two phase 3 randomised controlled
trials (RCTs), rifaximin 550 mg t.d.s. for 14 days is the
recommended dose.3 The third RCT discussed in our
study is a phase 2 dose-ranging study to identify the
ideal dose for treatment of non-C IBS.4
Third, it is true that the incremental beneﬁt of rifaximin
over placebo for improvement in global IBS symptoms is
9% (40.7% vs. 31.7%). However, in rigorously designed
RCTs, IBS treatments with proven efﬁcacy for global
IBS symptoms consistently show beneﬁts of approxi-
mately 10% over placebo.5 Further data are needed about
long-term management with rifaximin. This is being stud-
ied in an RCT of over 1000 patients and data will be avail-
able later in 2014.
Finally, there is controversy about the diagnosis of
small intestinal bacterial overgrowth (SIBO) with breath
testing. However, the patients in these RCTs did not
undergo breath testing and the decision to treat was
based solely on the presence of non-C IBS symptoms.
We therefore do not think that criticisms about breath
testing apply. In fact, the impact of rifaximin may not be
limited to treatment of SIBO. Rifaximin may alter the
interaction between bacterial ﬂora and the immune sys-
tem in the colonic mucosa, and this is being explored in
the Target 3 study.
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Transarterial chemoembolisation (TACE) is considered
the standard treatment for intermediate-stage (BCLC
stage B) hepatocellular carcinoma (HCC).1 A meta-analy-
sis revealed highly variable objective response rates
between 16% and 61%, which did not always translate
into improved survival.2 TACE was also not a well-
deﬁned and homogenous technique across different
units.
Embolisation material has evolved over time. Micro-
spheres allowed occlusion of target vessels at a desired
point by selecting an appropriate particle size, com-
pared with conventional particulate agents, such as gel-
atin sponge or polyvinyl alcohol particles.3 Drug-eluting
beads (DEB) have been recently developed, which can
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